Experience

Davis Polk advised Dufry AG (Dufry) and its subsidiary, Hudson Ltd., in connection with the $748.9 million initial public offering of 39,417,765 Class A common shares of Hudson Ltd. The…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares…

Davis Polk advised Ultra Clean Holdings, Inc. on its SEC-registered follow-on public offering of 4,761,905 shares of common stock for an aggregate price to the public of approximately $100…

Davis Polk advised Natura Cosméticos S.A. in connection with its $750 million offering of 5.375% senior notes due 2023, which were issued pursuant to Rule 144A and Regulation S under the…

Davis Polk is advising the joint lead arrangers, joint bookrunners and the administrative agent in connection with a $2.5 billion unsecured bridge facility to be…

Davis Polk advised Grupo Financiero Santander México, S.A.B. de C.V. (“Grupo Financiero Santander México”) and Banco Santander (México), S.A., Institución de Banca Múltiple, Grupo…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Varian Medical Systems, Inc. in connection with its approximately A$1.6 billion acquisition of Sirtex Medical…

Davis Polk advised Auris Medical Holding AG on its registered direct offering of 12,499,999 of its common shares and concurrent private placement of warrants to purchase up to 7,499,999 of…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk advised one of the joint global coordinators for the placement of up to 450,000,000 new shares in Beijing Enterprises Water Group Limited (“BEWGL”) for a total consideration of…